CRRT with Oxiris hemofilter as a new potential therapy in COVID-19: a case series

References (6)

1. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061-9
2. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46:846-8
3. Chu KH, Tsang WK, Tang CS, Lam MF, Lai FM, To KF et al. Acute renal impairment in coronavirusassociated severe acute respiratory syndrome. Kidney Int. 2005;67:698-705
4. Malard B, Lambert C, Kellum JA. In vitro comparison of the adsorption of inflammatory mediators by blood purification devices. Intensive Care Med Exp. 2018;6:12
5. Broman ME, Hansson F, Vincent JL, Bodelsson M. Endotoxin and cytokine reducing properties of the oXiris membrane in patients with septic shock: A randomized crossover double-blind study. PLoS One. 2019;14:e0220444
6. Turani F, Barchetta R, Falco M, Busatti S, Weltert L. Continuous renal replacement therapy with the adsorbing filter oXiris in septic patients: a case series. Blood Purif. 2019;47(Suppl 3):1-5.